New drugs: Maraviroc and Lanreotide.
Hussar
Daniel A
DA
Philadelphia College of Pharmacy, University of the Sciences, Philadelphia, USA.
D000172:Acromegaly / Q000188:drug therapy*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003510:Cyclohexanes / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D023581:HIV Fusion Inhibitors / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D000077592:Maraviroc; D010456:Peptides, Cyclic / Q000009:adverse effects / Q000627:therapeutic use*; D013004:Somatostatin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014230:Triazoles / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D003510:Cyclohexanes; D023581:HIV Fusion Inhibitors; D010456:Peptides, Cyclic; D014230:Triazoles; C060347:lanreotide; D013004:Somatostatin; D000077592:Maraviroc